
Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 16, 2022

Booster Fatigue, Vaccines are for Kids, and Other Obstacles to Adult Immunization in Primary Care

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

After exposure to COVID-19, asymptomatic individuals in low-risk settings no longer need to quarantine, says the CDC; masking is still recommended.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Influenza, SARS-CoV-2, and RSV: 4 drug makers have all 3 viruses targeted for vaccines, alone and in combination. Click through the flash-card update.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Infectious disease specialist Rodger MacArthur, MD, took a long-awaited vacation--and got COVID. He shares his conclusions about the BA.5 variant in particular.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Type 1 diabetes diagnoses increased by 81% during the 4-week acute phase of COVID-19 in UK patients and CVD diagnoses rose 6-fold, according to a large population-based study.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Findings showed neutralizing antibody responses to BA.4 and BA.5 subvariants were approximately 20-fold lower than to the original WA1/2020 strain.

The FDA's move could potentially improve Paxlovid access for patients at high risk for severe COVID-19 who have limited access to health care.